Keensight Capital, a private equity manager, has acquired a majority stake in regenerative medtech company Isto Biologics from Thompson Street Capital Partners.
Isto Biologics develops and manufactures orthobiologic products to aid the healing process, according to a Sept. 17 news release from Thompson Street Capital Partners.
Keensight will continue to accelerate Isto’s growth strategy through organic expansion and acquisitions.
More than 400 hospitals and clinics, primarily in the U.S., purchase products from Isto Biologics.
Thompson Street Capital Partners will retain a minority stake alongside Isto Biologics’ management team, the release said.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
